Could patients with smIPI >1 and poor tolerability to R-CHOP be offered ISRT after 3 cycles of R-CHOP if interim PET showed 5-PS 1-3 response?
Given that older versions of NCCN guidelines for DLBCL recommended 3 cycles of R-CHOP before interim restaging and radiation therapy for nonbulky, Stage I DLBCL, what prompted the change in the guidelines so that smIPI 0-1 would have a different treatment pathway than smIPI > 1?
1 Answer
Mednet MemberInvited Expert
Radiation Oncology · Duke University Medical Center
Answered on · Updated on
The revised NCCN guidelines largely reflect data from studies demonstrating excellent outcomes with four cycles of R-CHOP in patients with low-risk diffuse large B-cell lymphoma (DLBCL), including FLYER, LYSA/GOELAMS, SWOG S1001, and the most recent trial, LNH2009-1B. Although each of these trials e...
Join for free or sign in to see the full answer